Top Midday Decliners

MT newswire2026/10/09 16:17

12:17 PM EDT, 10/09/2026 (MT Newswires) -- Verizon Communications (VZ), T-Mobile US (TMUS), and AT&T (T) shares fell after SpaceX's (SPCX) acquisition of low-band spectrum heightened concerns over growing competition from satellite-based mobile services. Verizon shares slumped nearly 10% as intraday trading volume soared to over 54 million from a daily average of about 21.8 million. T-Mobile shares sank past 12% as intraday trading volume soared to over 9 million from a daily average of roughly 4.6 million. AT&T shares dropped 10% as intraday trading volume jumped to over 87.5 million from a daily average of about 48.3 million. Alignment Healthcare (ALHC) expects the federal government to assign its California HMO plan, which provides health insurance to Medicare seniors, a lower star rating for 2027, it said late Thursday. Shares fell 14% as intraday trading volume surged to over 16.3 million from a daily average of about 7.5 million. Price: 41.28, Change: -4.37, Percent Change: -9.57

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

BUZZ - Citi optimistic about rebound in commodity prices, Australian energy stocks surge

路透社•2026/10/13 00:21

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11